The University of Michigan Comprehensive Cancer Center (UMCCC) requests renewal of its core grant in support of senior leadership, programs and shared facilities. The Cancer Center was established by the Board of Regents in 1989 to provide a focus for all cancer related activities throughout the University. A core grant to support the UMCCC was initially awarded by the NCI in 1988 and renewed for 5 years in 1991. The Center provides an organizational framework to promote interdisciplinary research through the development of defined clinical, basic science and prevention programs in cancer research, and the development and support of shared resources. There are ten clinical research programs including eight representing coordinated research efforts of cancers of major organ systems: breast, prostate, thorax, brain, gastrointestinal tract, cutaneous leukemia/lymphoma and pediatric tumors. In addition, there are programs in radiation oncology research and radiopharmaceuticals development. The five basic science research programs of the Center included molecular oncology, tumor metastasis and extracellular matrix, tumor immunology, cancer pharmacology, and drug discovery and development. The Center proposes two new programs in carcinogenesis and cancer prevention. Support is requested for 11 shared core facilities, including clinical trials, biostatistics, tissue procurement, tumor imaging, molecular biology and protein chemistry, morphology, flow cytometry, experimental radiation, animal facility, transgenic mouse and vector cores. The Cancer Center senior leadership is composed of the director and five associate directors, including one each for clinical research, clinical affairs, basic science research, for prevention and control research and for administration. The University and the Medical Center have made substantial commitments to the Cancer Center including the construction of a new $88 million facility to house the Center's outpatient clinics and research laboratories. The 285 Cancer Center members receive over $55 million in research and training support. In the nine years since its establishment the UMCCC has had a major impact on cancer research at the University of Michigan.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046592-10S2
Application #
2659866
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Project Start
1988-09-30
Project End
2001-05-31
Budget Start
1997-06-01
Budget End
1998-05-31
Support Year
10
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Jiagge, Evelyn; Jibril, Aisha Souleiman; Davis, Melissa et al. (2018) Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations. J Glob Oncol :1-8
Bowers, Emily; Slaughter, Anastasiya; Frenette, Paul S et al. (2018) Granulocyte-derived TNF? promotes vascular and hematopoietic regeneration in the bone marrow. Nat Med 24:95-102
Holt, Melissa C; Assar, Zahra; Beheshti Zavareh, Reza et al. (2018) Biochemical Characterization and Structure-Based Mutational Analysis Provide Insight into the Binding and Mechanism of Action of Novel Aspartate Aminotransferase Inhibitors. Biochemistry 57:6604-6614
Wang, Yin; Day, Mark L; Simeone, Diane M et al. (2018) 3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer. J Vis Exp :
Suresh, Krithika; Owen, Dawn; Bazzi, Latifa et al. (2018) Using Indocyanine Green Extraction to Predict Liver Function After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 100:131-137
O'Dwyer, David N; Zhou, Xiaofeng; Wilke, Carol A et al. (2018) Lung Dysbiosis, Inflammation, and Injury in Hematopoietic Cell Transplantation. Am J Respir Crit Care Med 198:1312-1321
El Kadi, Najwa; Wang, Luo; Davis, April et al. (2018) The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer. Cancer Res 78:6728-6735
Feng, Mary; Suresh, Krithika; Schipper, Matthew J et al. (2018) Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 4:40-47
Xiong, Yi; Torsoni, Adriana Souza; Wu, Feihua et al. (2018) Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases. Elife 7:
Eisenberg, Marisa C; Campredon, Lora P; Brouwer, Andrew F et al. (2018) Dynamics and Determinants of HPV Infection: The Michigan HPV and Oropharyngeal Cancer (M-HOC) Study. BMJ Open 8:e021618

Showing the most recent 10 out of 1493 publications